Alzheimer’s Disease/Dementia News

A phase 2 clinical trial has been initiated to evaluate the safety and efficacy of an inverse agonist for hallucinations and delusions associated with Alzheimer’s disease psychosis, according to the manufacturer.

Adults with a diagnosis of coronary heart disease before age 45 years are 36% more likely to develop dementia over 13 years of follow-up compared with those without a CHD diagnosis, data from the UK Biobank show.

Food insecurity was linked to an increased risk for dementia and faster memory decline among older adults, according to a study published in JAMA Network Open.

Having a higher amount of visceral abdominal fat in middle age was associated with an increased risk for developing Alzheimer’s disease, according to research presented at the annual meeting of the Radiological Society of North America.

The first patient has been enrolled in a European phase 2b clinical trial for AD04, a novel immunotherapy for the treatment of mild Alzheimer’s disease, according to the manufacturer.

For older adult males, negative changes in life space were associated with faster cognitive decline and increased risk for neurodegenerative disorders after 7 years, according to research from JAMA Network Open.

PHILADELPHIA — A 48-month intervention to lower BP in patients with uncontrolled hypertension also reduced risk for dementia and cognitive impairment, according to data presented at the American Heart Association Scientific Sessions.

Treatment with brexpiprazole 2 mg or 3 mg resulted in significant reduction in agitation over 12 weeks compared with placebo in adults with Alzheimer’s dementia, according to research published in JAMA Neurology.

The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.

A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to accelerate development of novel biomarkers for Alzheimer’s disease and related dementias.